Insulet Wins FDA Clearance for Enhanced Omnipod 5 Algorithm
Insulet Corporation has received FDA clearance for enhancements to its Omnipod 5 Automated Insulin Delivery System, including a lower glucose target and improved automated experience. These updates aim to simplify insulin delivery and improve outcomes for diabetes patients, launching in the US in early 2026.
Insulet Corporation has received FDA 510(k) clearance for significant enhancements to its Omnipod 5 Automated Insulin Delivery System. The newly approved updates include a lower 100 mg/dL target glucose option and improvements to the system’s automated experience, enabling users to stay in Automated Mode with fewer interruptions. These advancements are expected to launch in the United States in the first half of 2026, further simplifying insulin delivery and improving clinical outcomes for people with diabetes. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insulet Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251204178236) on December 04, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
